Kura Oncology
KURA
127 hedge funds and large institutions have $537M invested in Kura Oncology in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
49% more call options, than puts
Call options by funds: $233K | Put options by funds: $156K
9% more funds holding
Funds holding: 116 → 127 (+11)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.83% less ownership
Funds ownership: 88.99% → 86.16% (-2.8%)
12% less capital invested
Capital invested by funds: $610M → $537M (-$73.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.33M |
| 2 |
Goldman Sachs
New York
|
+$6.48M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.96M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.37M |
| 5 |
AG
Artal Group
Luxembourg
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$33.1M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$7.41M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.31M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.43M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.88M |
KURA Hedge Fund Activity: Q4 2019 in Review
127 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2019, worth a combined $537M — down 12% from $610M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KURA positions and 7 closed out — a net gain of 17 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $9.33M. The largest seller was Great Point Partners, cutting an estimated $33.1M.
- 127 institutional investors held Kura Oncology (KURA) as of Q4 2019, up from 116 in Q3 2019.
- Funds reported $537M of Kura Oncology stock for Q4 2019, down 12% quarter-over-quarter.
- 24 funds opened new Kura Oncology positions in Q4 2019 and 7 closed out, a net change of +17 holders.
- The largest Kura Oncology buyer in Q4 2019 was Millennium Management, an estimated $9.33M added.
- The largest Kura Oncology seller in Q4 2019 was Great Point Partners, an estimated $33.1M sold.
Based on aggregated 13F filings for Q4 2019.